ADAP
Price
$0.04
Change
-$0.01 (-20.00%)
Updated
Sep 5 closing price
Capitalization
10.87M
60 days until earnings call
CRSP
Price
$54.86
Change
+$2.12 (+4.02%)
Updated
Sep 5 closing price
Capitalization
4.99B
53 days until earnings call
Interact to see
Advertisement

ADAP vs CRSP

Header iconADAP vs CRSP Comparison
Open Charts ADAP vs CRSPBanner chart's image
Adaptimmune Therapeutics
Price$0.04
Change-$0.01 (-20.00%)
Volume$35.23M
Capitalization10.87M
CRISPR Therapeutics AG
Price$54.86
Change+$2.12 (+4.02%)
Volume$2.74M
Capitalization4.99B
ADAP vs CRSP Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. CRSP commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and CRSP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ADAP: $0.04 vs. CRSP: $54.86)
Brand notoriety: ADAP and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 74% vs. CRSP: 90%
Market capitalization -- ADAP: $10.87M vs. CRSP: $4.99B
ADAP [@Biotechnology] is valued at $10.87M. CRSP’s [@Biotechnology] market capitalization is $4.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, CRSP is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish while CRSP’s TA Score has 3 bullish TA indicator(s).

  • ADAP’s TA Score: 5 bullish, 2 bearish.
  • CRSP’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than CRSP.

Price Growth

ADAP (@Biotechnology) experienced а -30.39% price change this week, while CRSP (@Biotechnology) price change was +5.85% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 05, 2025.

CRSP is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.99B) has a higher market cap than ADAP($10.9M). CRSP YTD gains are higher at: 39.380 vs. ADAP (-92.389). ADAP has higher annual earnings (EBITDA): -149.75M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. ADAP (26.1M). ADAP has less debt than CRSP: ADAP (48.7M) vs CRSP (215M). ADAP has higher revenues than CRSP: ADAP (65.1M) vs CRSP (35M).
ADAPCRSPADAP / CRSP
Capitalization10.9M4.99B0%
EBITDA-149.75M-533.5M28%
Gain YTD-92.38939.380-235%
P/E RatioN/AN/A-
Revenue65.1M35M186%
Total Cash26.1M1.72B2%
Total Debt48.7M215M23%
FUNDAMENTALS RATINGS
ADAP vs CRSP: Fundamental Ratings
ADAP
CRSP
OUTLOOK RATING
1..100
8175
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
9849
P/E GROWTH RATING
1..100
10079
SEASONALITY SCORE
1..100
7565

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (47) in the Biotechnology industry is in the same range as CRSP (64). This means that ADAP’s stock grew similarly to CRSP’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that ADAP’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as ADAP (100). This means that CRSP’s stock grew similarly to ADAP’s over the last 12 months.

CRSP's Price Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for ADAP (98). This means that CRSP’s stock grew somewhat faster than ADAP’s over the last 12 months.

CRSP's P/E Growth Rating (79) in the Biotechnology industry is in the same range as ADAP (100). This means that CRSP’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPCRSP
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
N/A
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 9 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RARE31.820.54
+1.73%
Ultragenyx Pharmaceutical
ASX10.470.16
+1.55%
ASE Technology Holding Co Ltd
SKIL15.380.14
+0.92%
Skillsoft Corp
FLGT21.95-0.03
-0.14%
Fulgent Genetics
IMCC1.97-0.08
-3.90%
IM Cannabis Corp.

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with NEVPF. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-19.61%
NEVPF - ADAP
56%
Loosely correlated
N/A
AKBA - ADAP
41%
Loosely correlated
-1.99%
CSLLY - ADAP
32%
Poorly correlated
-0.58%
ATXS - ADAP
30%
Poorly correlated
+7.43%
CRSP - ADAP
30%
Poorly correlated
+4.02%
More

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+4.02%
RXRX - CRSP
68%
Closely correlated
+1.99%
BEAM - CRSP
66%
Loosely correlated
+12.62%
NTLA - CRSP
64%
Loosely correlated
+3.79%
CRBU - CRSP
59%
Loosely correlated
+1.08%
ABCL - CRSP
58%
Loosely correlated
+1.44%
More